All In Biotech

Drug Trial Radar · NCT03930615

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)

Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Jun 21, 2019

Primary completion

Oct 27, 2021

Study completion Mar 16, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

Conditions

  • Cytomegalovirus Infection

Interventions

  • LetermovirDrug

    LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).

  • PlaceboDrug

    Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplantTime frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center ( Site 0158)

    Duarte, California

  • University of California Davis Medical Center ( Site 0156)

    Sacramento, California

  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160)

    Miami, Florida

  • Indiana Blood and Marrow Transplantation ( Site 0175)

    Indianapolis, Indiana

  • Brigham & Women's Hospital ( Site 0161)

    Boston, Massachusetts

  • John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174)

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center ( Site 0164)

    New York, New York

  • Duke University Medical Center ( Site 0169)

    Durham, North Carolina

  • The University of Texas MD Anderson Cancer Center ( Site 0154)

    Houston, Texas

  • Fred Hutchinson Cancer Research Center ( Site 0152)

    Seattle, Washington

  • CHU Hopital Saint Antoine ( Site 0036)

    Paris, France

  • Centre Hospitalier Universitaire Dupuytren ( Site 0182)

    Limoges, Haute-Vienne, France

  • Hopital Saint Eloi ( Site 0031)

    Montpellier, Herault, France

  • Centre Hopitalier Lyon Sud ( Site 0039)

    Pierre-Bénite, Rhone, France

  • CHU Henri Mondor ( Site 0032)

    Créteil, Val-de-Marne, France

  • Institut Gustave Roussy ( Site 0038)

    Villejuif, Val-de-Marne, France

  • Universitaetsklinikum Heidelberg-Medizinische Klinik V ( Site 0042)

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitaetsklinik Koeln ( Site 0041)

    Cologne, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Muenster ( Site 0043)

    Münster, North Rhine-Westphalia, Germany

  • IRCCS Ospedale San Raffaele ( Site 0051)

    Milan, Italy

  • Fondazione PTV Policlinico Tor Vergata ( Site 0054)

    Roma, Italy

  • Policlinico Umberto I ( Site 0056)

    Roma, Italy

  • Policlinico Universitario Agostino Gemelli ( Site 0055)

    Roma, Italy

  • ASST Spedali Civili di Brescia ( Site 0052)

    Brescia, Lombardy, Italy

  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 0121)

    Hiroshima, Japan

  • National Hospital Organization Kumamoto Medical Center ( Site 0122)

    Kumamoto, Japan

  • Jichi Medical University Hospital ( Site 0123)

    Shimotsuke, Tochigi, Japan

  • Manchester Royal Infirmary ( Site 0097)

    Manchester, United Kingdom

  • Freeman Hospital Newcastle upon Tyne Foundation NHS Trust ( Site 0092)

    Newcastle upon Tyne, United Kingdom

  • Queen Elizabeth University Hospital [Glasgow, UK] ( Site 0096)

    Glasgow, Glasgow City, United Kingdom

  • 1Kings College Hospital ( Site 0091)

    London, London, City of, United Kingdom

  • UCL Cancer Institute ( Site 0093)

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.